Patents by Inventor Robin Wood
Robin Wood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939837Abstract: Provided is a clutch assembly, a SSSV, and a method for operating an SSSV. The clutch assembly, in one aspect, includes an output coupler housing, an input shaft, and an electromagnet coupled to the input shaft. In at least one aspect, the electromagnet is configured to axially translate the output coupler housing from a de-coupled state to a coupled state when the electromagnet is energized. The clutch assembly, in one aspect, further includes one or more grooves located in one of an outer surface of the input shaft or an inner surface of the central opening, and one or more engagement members located in the other of the inner surface of the central opening or the outer surface of the input shaft.Type: GrantFiled: June 24, 2022Date of Patent: March 26, 2024Assignee: Halliburton Energy Services, Inc.Inventors: Nicholas Robert Wood, Kevin Robin Passmore, Bruce Edward Scott, Jon-Howard Elliott Hanson
-
Patent number: 11913944Abstract: Provided herein are compositions and methods for photoaffinity labeling of molecular targets. In particular, probes that specifically interact with cellular targets based on their affinity and are then covalently linked to the cellular target via a photoreactive group (PRG) on the probe.Type: GrantFiled: March 20, 2020Date of Patent: February 27, 2024Assignee: Promega CorporationInventors: Sergiy Levin, Rachel Friedman Ohana, Robin Hurst, Thomas Kirkland, Keith Wood
-
Publication number: 20220322963Abstract: Disclosed are methods and devices for analyzing exhaled breath aerosols and exhaled breath condensates using various diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for analyzing exhaled breath aerosols and exhaled breath condensates for tuberculosis diagnosis using mass spectrometry, including MALDI-MS. The disclosed systems and methods provide for a diagnostic test result in less than about 20 minutes and provides for autonomous operation with minimal human intervention.Type: ApplicationFiled: August 26, 2020Publication date: October 13, 2022Applicant: Zeteo Tech, Inc.Inventors: WAYNE A. BRYDEN, Charles J. Call, Robin Wood, Dapeng Chen
-
Publication number: 20150113923Abstract: A horse mask having a removable visor is provided. The horse mask is composed of a flexible mesh material and is adapted to substantially cover a horse's head. The horse mask comprises an opening thereon corresponding to the location of the horse's eyes and area therebetween. The opening includes a fastener disposed about the perimeter thereof to which a visor can be removably secured. The visor is transparent and serves to shield the horse's eyes from exposure to ultraviolet radiation. Preferably, the visor is secured to the opening of the mask using hook and loop fastening material. The mask further includes a pair of pockets having an interior volume in which a horse's ears can be positioned. The mask can be secured on a horse by overlapping portions of the mask on an underside of the horse's head.Type: ApplicationFiled: September 23, 2014Publication date: April 30, 2015Inventor: Robin Wood
-
Publication number: 20090306116Abstract: A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.Type: ApplicationFiled: September 13, 2006Publication date: December 10, 2009Applicant: AstraZeneca ABInventors: Andrew Peter Thomas, Robin Wood
-
Patent number: 6313127Abstract: Compounds of formula (I) in which all variables are defined in the description and their salts inhibit the enzyme oxido squalene cyclase and are useful in treating hypercholesterolemia and also as anti-fungal agents. Processes for their preparation are also described together with their use in medicine.Type: GrantFiled: July 31, 1998Date of Patent: November 6, 2001Assignee: Zeneca LimitedInventors: David Waterson, Elaine Sophie Elizabeth Stokes, George Robert Brown, John Graham Cumming, Nicholas John Newcombe, Robin Wood, William John Watkins
-
Patent number: 6090813Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T.sup.1, T.sup.2 and T.sup.3 are selected from CH and N; provided that T.sup.2 and T.sup.3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T.sup.2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.Type: GrantFiled: February 13, 1998Date of Patent: July 18, 2000Assignee: Zeneca LimitedInventors: David Waterson, Elaine Sophie Elizabeth Stokes, George Robert Brown, Robin Wood
-
Patent number: 5294620Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ra, Rb, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: April 2, 1993Date of Patent: March 15, 1994Assignee: Imperial Chemical Industries PLCInventors: Arnold H. Ratcliffe, Robert J. Pearce, Keith H. Gibson, Robin Wood, Brian B. Masek
-
Patent number: 5217976Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ra, Rb, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: May 29, 1992Date of Patent: June 8, 1993Assignee: Imperial Chemical Industries PLCInventors: Arnold H. Ratcliffe, Robert J. Pearce, Keith H. Gibson, Robin Wood, Brian B. Masek
-
Patent number: 4581366Abstract: The invention concerns 1'-(4-bromo-2-fluorobenzyl)-7'-chloro-spiro[imidazolidine-4,3'-indoline]-2 ,2',5-trione in racemic or dextrorotatory form; pharmaceutical compositions thereof for use in the treatment or prophylaxis of certain complications of diabetes; and processes for its manufacture.Type: GrantFiled: March 19, 1984Date of Patent: April 8, 1986Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4544662Abstract: The invention provides novel spiro[oxazolidine-5,3'-indoline]-2,2',4-triones of formula I bearing substituted benzyl or cinnamyl on the indoline nitrogen, together with salts and non-toxic, biodegradable precursors thereof. The compounds are potent inhibitors of the enzyme aldose reductase and are useful in treating or preventing certain diabetic complications. The invention also provides pharmaceutical compositions containing, and processes for the manufacture of, the compounds of formula I and their salts and derivatives.Type: GrantFiled: May 6, 1983Date of Patent: October 1, 1985Assignee: Imperial Chemical IndustriesInventors: David R. Brittain, Robin Wood
-
Patent number: 4539329Abstract: The invention concerns novel trifluoromethyl derivatives of 1'-halogenobenzyl-spiro[imidazolidine-4,3'-indoline]-2,2',5-trione (I), their pharmaceutically acceptable salts, and non-toxic, biodegradable precursors thereof. The derivatives are potent inhibitors of the enzyme aldose reductase and are useful in treating or preventing certain complications of diabetes. The invention also provides pharmaceutical compositions and processes for the manufacture of the derivatives.Type: GrantFiled: May 6, 1983Date of Patent: September 3, 1985Assignee: Imperial Chemical Industries, plcInventors: David R. Brittain, David Brown, Robin Wood
-
Patent number: 4523021Abstract: The invention provides a pharmaceutical composition comprising an aldose reductase inhibitory 1'substituted-spiro[pyrrolidine-3,3'-indoline]-2,2',5-trione of the formula: ##STR1## wherein Ra is (2-7C)alkyl or (3-7C)alkenyl, naphthylmethyl or cinnamyl optionally bearing one or two halogeno nuclear substituents, or Ra is benzyl optionally bearing one or two substituents and benzene ring A optionally bears one or two substituents, trifluoromethyl and nitro; or a salt thereof with a base affording a pharmaceutically acceptable cation; or a non-toxic, biodegradable precursor thereof; together with a pharmaceutically acceptable diluent or carrier. The invention also provides novel compounds of formula I and processes for their manufacture.The compositions are of application in the treatment or prophylaxis of the side effects of diabetes or galactosemia.Type: GrantFiled: August 7, 1984Date of Patent: June 11, 1985Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4503066Abstract: The invention provides various medical compositions for use in treating or preventing certain of the side effects of diabetes or galactosemia. The active ingredients are selected from a series of novel aldose reductase inhibitory spiro-linked pyrrolidine-2,5-diones of the general formula: ##STR1## or a pharmaceutically acceptable salt, or a non-toxic, biodegradable precursor thereof. Processes for the production of these compounds are also provided. A particular compound suitable for use as an active ingredient is spiro[pyrrolidine-3,9'-xanthene]-2,5-dione.Type: GrantFiled: May 11, 1982Date of Patent: March 5, 1985Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4490381Abstract: The invention concerns novel 1'-substituted spiro[imidazolidine-4,3'-indoline]-2,2',5-triones of the formula: ##STR1## in which R.sup.1 is (1-12C)alkyl; phenyl, naphthylmethyl or cinnamyl optionally bearing 1-2 halogeno substituents; or benzyl optionally bearing 1-3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)-alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; and ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or two substituents independently selected from halogeno (1-4C)alkyl and nitro; or a pharmaceutically acceptable salt thereof; but excluding those compounds wherein R.sup.1 is methyl, ethyl, n-propyl or unsubstituted benzyl and benzene ring A is unsubstituted.The compounds of the invention are potent inhibitors of the enzyme aldose reductase and are of use in the treatment or prophylaxis of certain complications of diabetes or galactosemia.Type: GrantFiled: October 29, 1980Date of Patent: December 25, 1984Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4478847Abstract: The invention provides a pharmaceutical composition comprising an aldose reductase inhibitory 1'-substituted-spiro[pyrrolidine-3,3'-indoline]-2,2',5-trione of the formula: ##STR1## wherein Ra is (2-7C)alkyl or (3-7C)alkenyl, naphthylmethyl or cinnamyl optionally bearing one or two halogeno nuclear substituents, or Ra is benzyl optionally bearing one or two substituents and benzene ring A optionally bears one or two substituents, trifluoromethyl and nitro; or a salt thereof with a base affording a pharmaceutically acceptable cation; or a non-toxic, biodegradable precursor thereof; together with a pharmaceutically acceptable diluent or carrier. The invention also provides novel compounds of formula I and processes for their manufacture.The compositions are of application in the treatment or prophylaxis of the side effects of diabetes or galactosemia.Type: GrantFiled: May 11, 1982Date of Patent: October 23, 1984Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4443465Abstract: The invention provides an aldose reductase inhibitory pyrrole derivative of the formula: ##STR1## in which Ra is an optionally substituted benzyl or cinnamyl radical, and ring A is the benzene ring of an optionally substituted benzo[b]thiophene, benzo[b]furan, quinoline or N-alkylquinolone, together with pharmaceutically acceptable salts and non-toxic biodegradable precursors thereof.The compounds of formula I are useful in the treatment of prophylaxis of the side-effects of diabetes or galactosemia.Type: GrantFiled: May 11, 1982Date of Patent: April 17, 1984Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4393062Abstract: This invention relates to enzyme inhibitory, novel phthalazin-4-ylacetic acid derivatives of the general formula I: ##STR1## and pharmaceutically acceptable salts as appropriate, to pharmaceutical compositions thereof, and to analogy processes for their manufacture. The compounds of formula I are inhibitors of the enzyme aldose reductase in vivo and as such may be useful in the reduction or prevention of the development of the peripheral effects such as macular oedema, cataract, retinopathy or impaired neural conduction. A preferred compound is 2-(2-fluoro-4-bromobenzyl)-1,2-dihydro-1-oxophthalazin-4-ylacetic acid.Type: GrantFiled: October 6, 1980Date of Patent: July 12, 1983Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4386100Abstract: The invention provides novel non-toxic biodegradable derivatives of the formula: ##STR1## wherein Ra is (1-12C)alkyl, phenyl, naphthylmethyl or cinnamyl, the aromatic rings of which optionally bear one or two halogeno substituents, or Ra is benzyl optionally bearing up to 3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; Rb and Rc are independently selected from hydrogen and non-toxic biodegradable protecting radicals, but are not both hydrogen; and benzene ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or bears two substituents independently selected from halogeno, (1-4C)alkyl and nitro; pharmaceutical compositions thereof; and processes for their manufacture.The amides of formula I in which Rb.dbd.Rc.dbd.H are potent inhibitors of the enzyme aldose reductase.Type: GrantFiled: May 11, 1982Date of Patent: May 31, 1983Assignee: Imperial Chemical Industries PLCInventors: David R. Brittain, Robin Wood
-
Patent number: 4251528Abstract: This invention relates to enzyme inhibitory, novel phthalazin-4-ylacetic acid derivatives of the general formula I: ##STR1## and pharmaceutically acceptable salts as appropriate, to pharmaceutical compositions thereof, and to analogy processes for their manufacture. The compounds of formula I are inhibitors of the enzyme aldose reductase in vivo and as such may be useful in the reduction or prevention of the development of the peripheral effects such as macular oedema, cataract, retinopathy or impaired neural conduction. A preferred compound is 2-(2-fluoro-4-bromobenzyl)-1,2-dihydro-1-oxophthalazin-4-ylacetic acid.Type: GrantFiled: November 29, 1978Date of Patent: February 17, 1981Assignee: Imperial Chemical Industries LimitedInventors: David R. Brittain, Robin Wood